However, inhibiting ALK-Aug signaling to treat obesity may pose a challenge, as small molecular inhibitors of ALK that penetrate the blood–brain barrier can lead to weight gain, hypertriglyceridemia, hypercholesterolemia, and hypertension [73]. This evidence concerns the gene ALK and familial hypercholesterolemia.